Ai Kubo, PhD (*); Lyle Shlager, MD (*); Amy R. Marks, MPH; Dena Lakritz, RN, MPH; Colette Beaumont, RN, MSN; Kim Gabellini, RN, MS; Douglas A. Corley, MD, PhD
Disclaimer: The content of this publication does not necessarily reflect the views or policies of the National Institutes of Health, and the mention of trade names, commercial products, or organizations does not necessarily imply endorsement by the U.S. government. The authors assume full responsibility for the accuracy and completeness of the ideas presented.
Financial Support: By the Kaiser Permanente Community Benefit (grant CN-09LShla-01-H). Dr. Kubo is also supported by the National Cancer Institute and the National Institutes of Health Office of Research on Women's Health (career development award K07CA166143-01A1) and the National Center for Advancing Translational Sciences of the National Institutes of Health (KL2TR000143).
Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M13-2529.
Reproducible Research Statement: Study protocol: Available from Dr. Kubo (e-mail, email@example.com). Statistical code and data set: Not available.
Requests for Single Reprints: Ai Kubo, PhD, Kaiser Permanente Division of Research, 2000 Broadway, Oakland, CA 94612; e-mail, firstname.lastname@example.org.
Current Author Addresses: Drs. Kubo and Corley and Ms. Marks: Kaiser Permanente Division of Research, 2000 Broadway, Oakland, CA 94612.
Dr. Shlager: Kaiser Permanente San Francisco Medical Center, 2350 Geary Boulevard, San Francisco, CA 94115.
Ms. Lakritz, Ms. Beaumont, and Ms. Gabellini: Kaiser Permanente Oakland Medical Center, 3505 Broadway, Oakland, CA 94611.
Author Contributions: Conception and design: A. Kubo, L. Shlager, D. Lakritz, D.A. Corley.
Analysis and interpretation of the data: A. Kubo, L. Shlager, A.R. Marks, D. Lakritz, C. Beaumont, K. Gabellini, D.A. Corley.
Drafting of the article: A. Kubo, L. Shlager, A.R. Marks, D. Lakritz, D.A. Corley.
Critical revision of the article for important intellectual content: A. Kubo, L. Shlager, A.R. Marks, D. Lakritz, K. Gabellini, D.A. Corley.
Final approval of the article: A. Kubo, L. Shlager, D. Lakritz, K. Gabellini, D.A. Corley,
Provision of study materials or patients: C. Beaumont.
Statistical expertise: A.R. Marks, D.A. Corley.
Obtaining of funding: A. Kubo, L. Shlager, D.A. Corley.
Administrative, technical, or logistic support: A.R. Marks, D. Lakritz, K. Gabellini.
Collection and assembly of data: A. Kubo, A.R. Marks, D. Lakritz, C. Beaumont, K. Gabellini, D.A. Corley.
For mothers with chronic hepatitis B virus (HBV) infection, the Centers for Disease Control and Prevention recommends immunoprophylaxis to decrease perinatal transmission. However, its effectiveness and risk factors for failure have not been well-studied in community practice.
To investigate the effectiveness of a contemporary immunoprophylaxis protocol.
An HBV perinatal immunoprophylaxis program within Kaiser Permanente Northern California.
4446 infants born to 3253 HBV-positive mothers between 1997 and 2010.
Adherence to immunoprophylaxis, follow-up testing rates, maternal risk factors for HBV transmission, and transmission rates.
The infant infection rate was 0.75 per 100 births from 1997 to 2010 (Poisson 95% CI, 0.48 to 1.10). Rates per 100 births were 3.37 (CI, 2.08 to 5.14) for e antigen–positive mothers and 0.04 (CI, 0.001 to 0.24) for e antigen–negative mothers. Among mothers with viral load testing, the lowest level associated with transmission was 6.32 × 107 IU/mL. Infection rates per 100 births were 3.61 (CI, 0.75 to 10.56) among the 83 births to mothers with viral loads of 5 × 107 IU/mL or greater and 0 among the 831 births to mothers with viral loads less than 5 × 107 IU/mL, regardless of e antigen status.
Testing for HBV immunity and infection was less complete in earlier years. Viral load testing was only consistently available starting in 2007.
Prenatal HBV screening followed by postnatal prophylaxis is highly effective in preventing vertical transmission of HBV. A negative e antigen status or a viral load less than 5 × 107 IU/mL (90.9% of women tested) identifies women at extremely low risk for transmission after immunoprophylaxis who are unlikely to benefit from further interventions.
Kaiser Permanente Community Benefit and National Institutes of Health.
Kubo A, Shlager L, Marks AR, Lakritz D, Beaumont C, Gabellini K, et al. Prevention of Vertical Transmission of Hepatitis B: An Observational Study. Ann Intern Med. 2014;160:828–835. doi: 10.7326/M13-2529
Download citation file:
Published: Ann Intern Med. 2014;160(12):828-835.
Gastroenterology/Hepatology, Infectious Disease, Liver Disease, Prevention/Screening, Viral Hepatitis.
Results provided by:
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use